German Cancer Prize

from Wikipedia, the free encyclopedia

The German Cancer Prize is a German science prize . The prize, worth a total of 22,500 euros (as of 2020), is awarded by the German Cancer Society in three categories: experimental, clinical and translational cancer research. The donor is the German Cancer Foundation , the foundation of the German Cancer Society. It has been awarded since 1986.

Award winners



  • Michael Stahl , senior internal physician at the Evangelical Huyssens Foundation (Essen) for his clinical and scientific contribution to the further development of interdisciplinary therapeutic strategies in the treatment of esophageal cancer ; clinical part.
  • Edward K. Geissler , Head of Experimental Surgery at the University of Regensburg for his animal experiments on the antiangiogenic and tumor suppressive effects of the mTOR inhibitor sirolimus and for the prospective and randomized patient study based on the findings; translational part.
  • Peter Friedl from the University Dermatology Clinic and the Rudolf Virchow Center for Experimental Biomedicine Würzburg for his work in the field of developing new imaging methods for investigating tumor invasion and his investigations into the mechanisms of tumor growth and metastasis; experimental part.




  • Axel Hauschild , Department of Dermatology, Venereology and Allergology at the University Hospital Kiel, for his clinical research in the field of dermatological oncology, particularly for the treatment of skin cancers such as melanoma , as well as for its commitment to creating clinical guidelines ; clinical part.
  • Heribert Jürgens , Head of the Clinic and Polyclinic for Pediatric and Adolescent Medicine, Pediatric Hematology and Oncology at the Münster University Hospital, for his clinical research on osteosarcomas , in particular with an Ewing tumor study, which led to an improvement in therapy, pathological understanding and the medical care for those affected; clinical part
  • Bernd Kaina , Institute for Toxicology at the University Hospital Mainz, for his work in researching the genetic principles of action of chemotherapeutic agents in solid tumors. His work has led to an improvement in the predictions of the response to cancer therapies, particularly for glioblastoma ; experimental part.


  • Michael Bamberg , radiation oncologist at the University Hospital of Tübingen, for his "trend-setting studies on the therapy of patients with brain tumors "; clinical part.
  • Florian Greten , II. Medical Clinic of the Technical University of Munich at the Klinikum rechts der Isar, for “Findings on the molecular pathology of colorectal cancer ”; experimental part.
  • Charlotte Niemeyer , Center for Pediatric and Adolescent Medicine at the University of Freiburg, for research on understanding the development of myelodysplastic syndromes ; translational part.


  • Volker Heinemann , Medical Clinic and Polyclinic III of the University Hospital Munich, for the improvement of diagnosis and therapy of gastrointestinal tumors and Alexander Katalinic , Institute for Social Medicine and Epidemiology at the University Hospital Schleswig-Holstein, for the development of an interactive cancer atlas and for the scientific-epidemiological evaluation for Preparation of skin cancer screening; clinical part
  • Lars Zender , Tübingen University Hospital, gastrointestinal oncology; for decoding certain cancer genes; experimental part
  • Stefan Pfister , Center for Pediatric and Adolescent Medicine at the University of Heidelberg, for his research on childhood brain tumors, and Roman Thomas , Department of Translational Genomics at the University of Cologne, for deciphering certain gene mutations in bronchial carcinoma; translational part


  • Martin Schrappe , Kiel University Hospital, for individualized therapy of acute lymphoblastic leukemia (ALL); clinical part
  • Simone Fulda , Goethe University Frankfurt, cell death mechanisms of various tumor types; translational part
  • Christoph Klein , University Hospital Regensburg; new concepts of tumor progression and metastasis; experimental part


  • Günter Klöppel , Munich, work in the field of pathology and the characterization of tumors of the pancreas; clinical research
  • Wolfgang Wick , Heidelberg, new therapy standards in the treatment of gliomas; translational research
  • Lenhard Rudolph , Jena, role of telomeres in cancer and approaches for novel drugs against cancer; experimental research



  • Petra Boukamp , Heidelberg, development of skin cancer, and Martin Lipp , Berlin, chemokine receptors; experimental research
  • Guido Reifenberger , Düsseldorf, molecular causes of brain tumors; translational research
  • Michael Hallek , Cologne, molecular tumor biology in CLL; clinical research


  • Hartmut Goldschmidt , Heidelberg, therapy of multiple myeloma; clinical research
  • Michael Baumann , Heidelberg, individualized radiation therapy; translational research
  • Thomas Brabletz , Erlangen, migrating cancer stem cells; experimental research



Individual evidence

  1. ^ German Cancer Prize for child cancer researcher Prof. Henze. Science Information Service, accessed on March 21, 2009 .
  2. Cancer Prize for Dermatologists in Bochum. "Required reading online"; Institute for Journalism at the Technical University of Dortmund, accessed on March 1, 2010 .
  3. UKE researcher receives German Cancer Prize. Science Information Service, accessed on March 1, 2010 .
  4. Ivan Dikic receives the German Cancer Prize 2010. Science Information Service, accessed on March 1, 2010 .

Web links